Stock listing
LSE:0A8U Synlogic Inc Share Price
UK listing (LSE) of Synlogic Inc · home listing OTC:SYBX
Follow Synlogic Inc into a list and get an email when it puts out news.
Share price · LSE:0A8U
$0.96 USD -0.14 (-12.7%)
Close on Nov 20, 2026
- Day range
- $0.96 – $0.96 USDNov 20, 2026
- Volume
- 4,800 sharesNov 20, 2026
- 52-week range
- $0.54 – $1.63 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $668 USDMedian day 7 shares · 5 days with no trades · last 3 months, Sep 2, 2026 – Nov 4, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:SYBX · Home | $0.96 USD | -0.023 (-2.4%) | 4,352 | $0.96 | $0.967 | $0.96 | $0.984 | Close on Nov 20, 2026 |
| LSE:0A8U | $0.96 USD | -0.14 (-12.7%) | 4,800 | $0.96 | $0.96 | $0.96 | $1.10 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Sep 2, 2026 – Nov 4, 2026 · LSE:0A8U · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.93 | -0.03 | -3.1% | $0.93 | $0.93 | $0.93 | 140 | |
| $0.96 | 0.00 | 0.0% | $0.96 | $0.96 | $0.96 | 0 | |
| $0.96 | 0.00 | 0.0% | $0.96 | $0.96 | $0.96 | 0 | |
| $0.96 | -0.005 | -0.5% | $0.965 | $0.965 | $0.96 | 949 | |
| $0.965 | 0.00 | 0.0% | $0.965 | $0.965 | $0.965 | 0 | |
| $0.965 | 0.00 | 0.0% | $0.965 | $0.965 | $0.965 | 0 | |
| $0.965 | 0.00 | 0.0% | $0.965 | $0.965 | $0.965 | 0 | |
| $0.965 | -0.035 | -3.5% | $0.965 | $0.965 | $0.965 | 9 | |
| $1.00 | -0.07 | -6.5% | $1.00 | $1.00 | $1.00 | 994 | |
| $1.07 | 0.00 | 0.0% | $1.07 | $1.07 | $1.07 | 4 | |
| $1.07 | -0.04 | -3.6% | $1.10 | $1.11 | $1.07 | 1 | |
| $1.11 | 0.00 | 0.0% | $1.10 | $1.11 | $1.10 | 300 | |
| $1.11 | -0.05 | -4.3% | $1.11 | $1.11 | $1.11 | 2,806 | |
| $1.16 | +0.01 | +0.9% | $1.13 | $1.16 | $1.13 | 5,513 | |
| $1.15 | -0.02 | -1.7% | $1.12 | $1.15 | $1.12 | 899 | |
| $1.17 | +0.02 | +1.7% | $1.17 | $1.17 | $1.17 | 100 | |
| $1.15 | -0.09 | -7.3% | $1.15 | $1.15 | $1.15 | 2 | |
| $1.24 | +0.09 | +7.8% | $1.24 | $1.24 | $1.24 | 2 | |
| $1.15 | -0.23 | -16.7% | $1.15 | $1.15 | $1.15 | 270 | |
| $1.38 | +0.15 | +12.2% | $1.25 | $1.38 | $1.25 | 1 |
Splits
1 split · LSE:0A8U · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation |
- Ticker
- LSE:0A8U
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- USD
Synlogic Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Calls
- 8 calls with a replay · 8 with a transcript · latest Aug 11, 2022
- Decks
- 26 decks · latest Jan 17, 2024
Where Synlogic Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| OTC:SYBX · Home listing | OTC | United States | USD |
| LSE:0A8U · This page | LSE | United Kingdom | USD |
Valuation
Price/book 1.2× against a median of 4.5×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $201,442 USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.50
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.54M | US$19.53M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Median of the others | US$11.66M | US$11.52M | 15.7× | 4.5× | −267.8% | 0.7× | 0.72 |
Forecasts
1 hold · Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 USD · Analysts' mean
Team and board
Officers
| Officer | Role |
|---|---|
| Aoife Brennan | President and Chief Executive Officer |
| Mary Beth Dooley | Principal Executive Officer and Principal Financial Officer |
Board
| Director | Role |
|---|---|
| Peter Barrett | Chairman, Partner, Atlas Venture |
Events
Calls
| Call | When | Status |
|---|---|---|
| Synlogic (OTC:SYBX) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q1 2022 Earnings Call | Thu, May 12, 2022 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q4 2021 Earnings Call | Thu, Mar 17, 2022 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q2 2021 Earnings Call | Thu, Aug 12, 2021 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q1 2021 Earnings Call | Thu, May 13, 2021 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q4 2020 Earnings Call | Thu, Mar 25, 2021 · 8:30 AM ET | Replay |
| Synlogic (OTC:SYBX) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 | |
| Q2 2026 | Aug 12, 2026 | +4.2% |
| Q1 2026 | May 29, 2026 | +3.0% |
| Q4 2025 | Mar 17, 2026 | +9.4% |
| Q3 2025 | Nov 13, 2025 | 0.0% |
| Q2 2025 | Aug 7, 2025 | +1.4% |
| Q1 2025 | May 12, 2025 · Before open | +0.5% |
| Q4 2024 | Mar 6, 2025 · After close | +0.4% |
| Q3 2024 | Nov 12, 2024 · After close | −3.4% |
| Q2 2024 | Aug 8, 2024 · Before open | −4.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −2.8% |
| Q4 2023 | Mar 19, 2024 · Before open | −6.3% |
| Q3 2023 | Nov 9, 2023 · Before open | −15.0% |
| Q2 2023 | Aug 10, 2023 · Before open | +1.5% |
| Q1 2023 | May 11, 2023 · Before open | +0.5% |
| Q4 2022 | Mar 29, 2023 · Before open | +2.9% |
| Q3 2022 | Nov 10, 2022 · Before open | −6.9% |
| Q2 2022 | Aug 11, 2022 · Before open | +11.2% |
| Q1 2022 | May 12, 2022 · Before open | −14.4% |
| Q4 2021 | Mar 17, 2022 · Before open | −4.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Sidoti Micro-Cap Virtual Conference 2024 | Conference | 14 slides | Jan 17, 2024 |
| Investor Presentation (January 2024) | Investor deck | 33 slides | January 2024 |
| Technical Presentation (December 2022) | Technical | 26 slides | Dec 15, 2022 |
| Technical Presentation (October 2022) | Technical | 24 slides | Oct 18, 2022 |
| FY2021 Earnings Presentation | Earnings | 22 slides | Mar 17, 2022 |
| Q3 2021 Earnings Presentation | Earnings | 25 slides | Nov 10, 2021 |
| Investor Presentation (September 2021) | Investor deck | 49 slides | Sep 20, 2021 |
| Corporate Update (September 2021) | Corporate update | 29 slides | Sep 20, 2021 |
| Investor Presentation (August 2021) | Investor deck | 43 slides | Aug 12, 2021 |
| Q2 2021 Earnings Presentation | Earnings | 20 slides | Aug 12, 2021 |
All 26 decks
IPO
Went public as Mirna Therapeutics, Inc. Priced at US$7.00 a share on Sep 30, 2015.
- Price
- US$7.00 a share
- Shares offered
- 6,250,000 shares of common stock
- Offering size
- US$43.8 million
- Underwriters' option
- Up to 937,500 more shares
- Listing
- MIRN on the Nasdaq Global Market
- Underwriters
- Citigroup, Leerink Partners, Oppenheimer & Co., Cantor Fitzgerald & Co. · In the order on the cover
- Shares delivered
- On or about Oct 6, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 12, 2014 |
| Filed publicly | Aug 24, 2015 |
| Amended 5 times | Newest Sep 30, 2015 |
| Shares registered with an exchange | Sep 23, 2015 |
| Declared effective by the SEC | Sep 30, 2015 |
| Final prospectus, with the price | Oct 1, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 1, 2015 |
| EFFECT · Notice that a registration is effective | Sep 30, 2015 |
| FWP · Free writing prospectus | Sep 30, 2015 |
| S-1/A · Registration statement, amended | Sep 30, 2015 |
| S-1/A · Registration statement, amended | Sep 29, 2015 |
| CORRESP · Letter to the SEC | Sep 25, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Sep 25, 2015 |
| S-1/A · Registration statement, amended | Sep 25, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 23, 2015 |
| S-1/A · Registration statement, amended | Sep 18, 2015 |
All 24 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Sep 11, 2015 |
| CORRESP · Letter to the SEC | Sep 2, 2015 |
| CORRESP · Letter to the SEC | Aug 24, 2015 |
| S-1 · Registration statement | Aug 24, 2015 |
| UPLOAD · Letter from the SEC | Aug 13, 2015 |
| DRS/A · Draft registration statement, amended | Jul 15, 2015 |
| DRSLTR · Letter to the SEC with a draft | May 13, 2014 |
| DRS/A · Draft registration statement, amended | May 13, 2014 |
| UPLOAD · Letter from the SEC | May 6, 2014 |
| DRSLTR · Letter to the SEC with a draft | Apr 22, 2014 |
| DRS/A · Draft registration statement, amended | Apr 22, 2014 |
| UPLOAD · Letter from the SEC | Apr 9, 2014 |
| DRS/A · Draft registration statement, amended | Apr 4, 2014 |
| DRS · Draft registration statement | Mar 12, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 1, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 8.00K | 3.37M | 1.18M | 1.75M | 545.0K | 2.22M | 2.52M | 2.44M | 444.0K |
| Research and development | 43.0K | 9.15M | 44.0M | 52.0M | 47.1M | 47.5M | 41.9M | 38.0M | 30.3M | 15.0M |
| Operating income | -4.01M | -41.0M | -55.2M | -67.4M | -60.8M | -60.5M | -54.4M | -51.2M | -40.8M | -21.0M |
| Depreciation and amortization | 0 | 347.0K | 1.96M | 2.52M | 2.44M | 2.64M | 2.70M | 2.42M | 2.31M | 159.0K |
| EBITDA | -4.01M | -40.6M | -53.2M | -64.9M | -58.3M | -57.8M | -51.7M | -48.8M | -38.5M | -20.8M |
| Interest expense | 0 | 1.00K | 2.00K | 2.00K | 6.00K | 21.0K | 43.0K | 57.0K | 7.00K | |
| Income before tax | -1.00M | -23.4M | -61.3M | -66.1M | ||||||
| Income tax | 0 | 5.00K | 14.0K | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -1.00M | -23.4M | -61.3M | -66.1M | -60.6M | -59.2M | -51.4M | -48.4M | -40.4M | -21.0M |
| Earnings per share, basic | -0.08 | -1.92 | -9.42 | -13.83 | -1.09 | -1.65 | -1.70 | -2.03 | -6.00 | -1.26 |
| Earnings per share, diluted | -0.08 | -1.92 | -9.42 | -13.83 | -1.09 | -1.65 | -1.70 | -2.03 | -6.00 | -1.26 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.7M | 18.9M | 24.0M | 15.9M | 16.4M | 32.5M | 26.2M | 11.3M | 58.4M | 14.6M |
| Short-term investments | 0 | 23.8M | 61.8M | 112.2M | 67.9M | 93.4M | 111.5M | 28.6M | ||
| Current assets | 15.4M | 19.8M | 49.9M | 79.8M | 133.3M | 106.8M | 133.2M | 124.3M | 88.6M | 16.1M |
| Property, plant and equipment | 0 | 5.60M | 7.32M | 9.09M | 10.8M | 13.0M | 14.8M | 9.78M | 3.50M | |
| Total assets | 15.4M | 19.8M | 75.5M | 110.9M | 174.7M | 143.8M | 188.6M | 140.3M | 99.7M | 20.0M |
| Accounts payable | 103.0K | 164.0K | 1.46M | 1.78M | 1.94M | 2.00M | 2.17M | 2.42M | 2.68M | 988.0K |
| Current liabilities | 3.58M | 7.08M | 30.3M | 12.1M | 10.1M | 8.30M | 8.86M | 8.34M | 9.03M | 4.19M |
| Total liabilities | 3.81M | |||||||||
| Shareholders' equity | 11.9M | 12.8M | 32.8M | 82.6M | 147.3M | 115.1M | 156.9M | 124.1M | 85.0M | 8.50M |
| Shares outstanding | 11.7M | 11.7M | 9.19M | 4.45M | 69.7M | 38.2M | 32.3M | 25.4M | 16.3M | 0 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4.36M | -31.7M | -51.6M | -56.9M | -52.2M | -39.6M | -75.5M | -42.5M | -31.1M | -20.4M |
| Capital spending | 0 | -14.0K | -214.0K | -728.0K | -679.0K | -395.0K | -1.25M | -5.65M | -2.58M | -1.84M |
| Free cash flow | -4.36M | -31.7M | -51.8M | -57.6M | -52.9M | -39.9M | -76.7M | -48.1M | -33.6M | -22.2M |
| Cash from investing | 167.0K | 25.3M | 38.8M | 58.4M | -53.3M | 32.5M | 10.8M | -87.2M | 9.28M | -1.83M |
| Cash from financing | 0 | 172.0K | 20.9M | -2.04M | 89.4M | 13.4M | 79.6M | 82.5M | 66.7M | 30.6M |
| Change in cash | -4.19M | -6.15M | 8.10M | -577.0K | -16.1M | 6.32M | 14.9M | -47.2M | 44.9M | 8.41M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 425 | Nov 5, 2026 | Other filings | SEC |
| 425 | Nov 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 29, 2026 | Big-stake notice | SEC |
| 425 | Jul 29, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 29, 2026 | Material contract | SEC |
| 25-NSE | May 18, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 6, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K/A · Current report, amended | Jan 29, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Nov 12, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 12, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Aug 15, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 14, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Dec 4, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Nov 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| DEF 14A · Proxy statement | Nov 5, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 5, 2024 | Annual report | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | May 16, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 144 · Notice of proposed sale | Apr 22, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Apr 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 21, 2024 | Management or board change | SEC |
| 144 · Notice of proposed sale | Mar 21, 2024 | Other filings | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| 8-K · Current report | Feb 22, 2024 | Management or board change | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 20, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 20, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Feb 16, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Feb 16, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 29, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 17, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 13, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 13, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 6, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 4, 2023 | Big-stake notice | SEC |
| 424B4 · Prospectus | Oct 2, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 29, 2023 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2023 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 28, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 28, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Sep 28, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 26, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 25, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 22, 2023 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Sep 20, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 15, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 11, 2023 | Other filings | SEC |
| S-1 · Registration statement | Sep 8, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 1, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 21, 2023 | Meeting notice | SEC |
| 8-K · Current report | Aug 16, 2023 | Material contract | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jun 5, 2023 | Current report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 1, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 1, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 21, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Apr 5, 2023 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 4, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 29, 2023 | Results | SEC |
| 10-K · Annual report | Mar 29, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 20, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 19, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2022 | Current report | SEC |
| 8-K · Current report | Dec 9, 2022 | Current report | SEC |
| 8-K · Current report | Nov 30, 2022 | Current report | SEC |
| 8-K · Current report | Nov 23, 2022 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 8-K · Current report | Oct 18, 2022 | Current report | SEC |
| 8-K · Current report | Sep 6, 2022 | Current report | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | May 25, 2022 | Insider trade | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2022 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2022 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2022 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2022 | Results | SEC |
| 10-K · Annual report | Mar 17, 2022 | Annual report | SEC |
| 4 · Change in ownership | Mar 3, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 3, 2022 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2022 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 8, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 1, 2022 | Insider trade | SEC |
| 8-K · Current report | Jan 24, 2022 | Material contract | SEC |
| 4 · Change in ownership | Jan 5, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2021 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2021 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 1, 2021 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 29, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Sep 23, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Sep 23, 2021 | Offer document | SEC |
| 424B5 · Prospectus | Sep 22, 2021 | Offer document | SEC |
| 8-K · Current report | Sep 20, 2021 | Current report | SEC |
| 8-K · Current report | Aug 12, 2021 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2021 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 2, 2021 | Other filings | SEC |
| 8-K · Current report | Jul 30, 2021 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jul 29, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 28, 2021 | Other filings | SEC |
| S-3 · Registration statement | Jul 23, 2021 | Offer document | SEC |
| 8-K · Current report | Jul 15, 2021 | Current report | SEC |
| 8-K · Current report | Jun 17, 2021 | Material contract | SEC |
| 4 · Change in ownership | Jun 14, 2021 | Insider trade | SEC |
This page holds 200 of 628 filings. Open Filings
Cap table
Built by 6ix from Synlogic Inc’s releases · as of Nov 3, 2026
- Common shares
- 12,248,950
- Fully diluted
- 12,248,950
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 12,248,950 | Nov 3, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 3, 2026 | 12,248,950 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Mathers Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); MBX Biosciences, Inc. (Director · Since at least Sep 12, 2024); Senti Biosciences Holdings, Inc. (Director · Since at least Jun 8, 2022); OnKure Therapeutics, Inc. (Director · Since at least Apr 8, 2021); Trevi Therapeutics, Inc. (Director · Since at least May 7, 2019); Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Inozyme Pharma Inc (Director · Jul 23, 2020 – Jun 18, 2024 · Past); Akouos Inc (Director · Jun 25, 2020 – Dec 1, 2022 · Past); Mirum Pharmaceuticals, Inc. (Director · Jul 17, 2019 – Jun 2, 2022 · Past); Ra Pharmaceuticals Inc (Director · Jun 28, 2018 – Apr 2, 2020 · Past) | Director · Dec 29, 2017 – Jun 22, 2023 · Past |
| Andrew Gengos Other companies: Immuneering Corporation (Chief Financial Officer and Treasurer · Since at least Jul 16, 2026); Turn Therapeutics Inc. (Director · Since at least Oct 7, 2025); Terns Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Feb 24, 2025); LeonaBio, Inc. (CFO and Chief Business Officer · May 18, 2023 – Sep 3, 2024 · Past); Cyteir Therapeutics Inc (Chief Business Officer · Jun 17, 2021 – Feb 22, 2022 · Past) | Chief Operating Officer · Oct 9, 2017 – Mar 14, 2018 · Past |
| Chau Quang Khuong Other companies: Damora Therapeutics, Inc. (Director · Oct 28, 2020 – Jun 14, 2023 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Whitehawk Therapeutics, Inc. (Director · Jun 18, 2019 – Jun 18, 2019 · Past); NextCure, Inc. (Director · May 8, 2019 – Jun 22, 2023 · Past); Inspire Medical Systems, Inc. (Director · Apr 10, 2019 – Oct 9, 2020 · Past) | Director · Jun 5, 2019 – Apr 20, 2021 · Past |
| Lawrence M. Alleva Other companies: Galera Therapeutics, Inc. (Director · Since at least Nov 6, 2019); Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Adaptimmune Therapeutics PLC (Chairman and Non-Executive Director · Since at least Jan 1, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past) | Director · Sep 30, 2015 – Jun 29, 2016 · Past |
| Anthony A Florence Jr Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Enliven Therapeutics, Inc. (Director · Dec 27, 2021 – Dec 27, 2021 · Past); Robinhood Markets, Inc. (Director · Jul 29, 2021 – May 2, 2022 · Past); Casper Sleep Inc (Director · Feb 6, 2020 – Jan 25, 2022 · Past) | Director · Since at least Jul 27, 2026 |
| Aoife Brennan Other companies: Climb Bio, Inc. (President and CEO, Director · Since at least Jun 27, 2024); Xilio Therapeutics, Inc. (Director · Since at least Jun 13, 2024); Kyntra Bio, Inc. (Director · May 26, 2021 – Jun 5, 2024 · Past) | President and CEO, Director · Mar 10, 2021 – Nov 10, 2023 · Past |
| James Flynn Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past) | Director · Mar 19, 2024 – Apr 26, 2025 · Past |
| Michael Powell Other companies: Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Checkmate Pharmaceuticals Inc (Director · Aug 6, 2020 – May 31, 2022 · Past); Galera Therapeutics, Inc. (Director · Nov 6, 2019 – Jun 14, 2023 · Past) | Director · Dec 29, 2017 – Jun 5, 2019 · Past |
| Peter Barrett Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026); Revvity, Inc. (Partner, Atlas Venture · Since at least May 6, 2022); Larimar Therapeutics, Inc. (Director · May 10, 2022 – May 10, 2022 · Past) | Chairman, Partner, Atlas Venture · Since at least Jun 9, 2022 |
| Gregg Beloff Other companies: Disc Medicine, Inc. (Chief Financial Officer · Feb 5, 2021 – Feb 5, 2021 · Past); Pandion Therapeutics Inc (See Remarks · Jul 16, 2020 – Apr 1, 2021 · Past) | See Remarks · Oct 21, 2019 – Dec 6, 2021 · Past |
All 17 people
| Person | Seat |
|---|---|
| Michael F Burgess Other companies: Turnstone Biologics Corp. (Interim Chief Medical Officer, Director · Jul 20, 2023 – Oct 16, 2023 · Past); SpringWorks Therapeutics Inc (Head of Research & Development · May 10, 2021 – Jul 18, 2022 · Past) | Director · Feb 3, 2020 – Jun 22, 2023 · Past |
| Nick Leschly Other companies: Bluebird bio Inc (Director · Since at least Oct 2, 2020); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past) | Director · Jun 10, 2021 – Jun 22, 2023 · Past |
| Casi DeYoung Other companies: Shattuck Labs, Inc. (Chief Business Officer · Since at least Oct 8, 2020) | Chief Business Officer · Sep 30, 2015 – Mar 11, 2016 · Past |
| Mohamad Makhzoumi Other companies: NeueHealth Inc (Director · Since at least Oct 31, 2023) | Director · Since at least Jul 27, 2026 |
| Mary Beth Dooley | Principal Executive Officer and Principal Financial Officer · Since at least Mar 18, 2024 |
| Paul Francis Miller | Chief Scientific Officer · Aug 28, 2017 – Feb 12, 2019 · Past |
| Richard J Riese | Chief Medical Officer · Sep 16, 2019 – Mar 10, 2021 · Past |
Log in to ask 6ix AI your own questions about Synlogic Inc.